PRICE T ROWE ASSOCIATES INC /MD/ - PROTAGONIST THERAPEUTICS INC ownership

PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 157 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of PROTAGONIST THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$41,912
+76.8%
1,209,542
+47.6%
0.01%
+66.7%
Q1 2024$23,703
+25.5%
819,296
-0.5%
0.00%0.0%
Q4 2023$18,889
+36.1%
823,740
-1.0%
0.00%
+50.0%
Q3 2023$13,879
-39.6%
831,993
+0.0%
0.00%
-33.3%
Q2 2023$22,972
+140.5%
831,693
+100.3%
0.00%
+200.0%
Q1 2023$9,552
-99.9%
415,274
+38.2%
0.00%0.0%
Q1 2022$7,115,000
-44.8%
300,468
-20.3%
0.00%0.0%
Q4 2021$12,898,000
+48.0%
377,132
-23.3%
0.00%0.0%
Q3 2021$8,712,000
-80.3%
491,641
-50.2%
0.00%
-75.0%
Q2 2021$44,263,000
+87.1%
986,254
+8.0%
0.00%
+100.0%
Q1 2021$23,662,000
+38.8%
913,590
+8.1%
0.00%0.0%
Q4 2020$17,043,000
+48.8%
845,395
+44.3%
0.00%
+100.0%
Q3 2020$11,454,000
-13.2%
585,859
-21.6%
0.00%
-50.0%
Q2 2020$13,203,000
+4286.4%
747,634
+1654.4%
0.00%
Q1 2020$301,000
+0.3%
42,616
+0.2%
0.00%
Q4 2019$300,000
-8.8%
42,516
+55.4%
0.00%
Q3 2019$329,000
+39.4%
27,365
+40.4%
0.00%
Q2 2019$236,000
+57.3%
19,486
+63.7%
0.00%
Q1 2019$150,000
+5.6%
11,900
-43.6%
0.00%
Q4 2018$142,000
-16.5%
21,100
+27.9%
0.00%
Q3 2018$170,000
+53.2%
16,5000.0%0.00%
Q2 2018$111,000
-21.8%
16,500
-0.3%
0.00%
Q1 2018$142,000
-30.4%
16,543
+68.4%
0.00%
Q4 2017$204,0009,8210.00%
Other shareholders
PROTAGONIST THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
JOHNSON & JOHNSON 2,449,183$84,864,19121.18%
Cannon Global Investment Management, LLC 69,900$2,422,03511.28%
ADAR1 Capital Management, LLC 1,603,932$55,576,24410.49%
Checkpoint Capital L.P. 355,000$12,300,7507.42%
Fairmount Funds Management LLC 931,890$32,289,9893.65%
BVF INC/IL 3,319,290$115,013,3993.22%
RTW INVESTMENTS, LP 5,286,404$183,173,8992.84%
Kynam Capital Management, LP 800,000$27,720,0002.14%
683 Capital Management, LLC 604,449$20,944,1581.58%
Birchview Capital, LP 48,000$1,663,2001.54%
View complete list of PROTAGONIST THERAPEUTICS INC shareholders